Home › Companies › HORIZON THERAPEUTICS PUBLIC LIMITED CO. › 2023-2024
Compiled from SEC Form N-PX filings and HORIZON THERAPEUTICS PUBLIC LIMITED CO.’s Form 8-K, filed July 28, 2023 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of July 27, 2023: 5 items on HORIZON THERAPEUTICS PUBLIC LIMITED CO.’s Form 8-K, filed July 28, 2023: 3 elected · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024
Explore HORIZON THERAPEUTICS PUBLIC LIMITED CO. in the interactive database Compare manager voting policies
These tallies are HORIZON THERAPEUTICS PUBLIC LIMITED CO.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed July 28, 2023 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Gino Santini | 151,483,008 | 5,400,292 | 276,244 | -- | 11,655,073 | 97% | Elected | — |
| Elect Director: James Shannon, M.D. | 131,479,967 | 25,396,734 | 282,843 | -- | 11,655,073 | 84% | Elected | — |
| Elect Director: Timothy P. Walbert | 142,310,378 | 14,398,120 | 451,046 | -- | 11,655,073 | 91% | Elected | — |
| 2. Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 and the authorization of the Audit Committee of our Board of Directors to determine the auditors' rem | 165,306,334 | 3,134,859 | 373,424 | -- | 0 | 98% | Not verified | — |
| 3. Approval, on an advisory basis, of the compensation of our named executive officers | 91,107,568 | 65,607,818 | 444,158 | -- | 11,655,073 | 58% | Not verified | — |
Source: HORIZON THERAPEUTICS PUBLIC LIMITED CO., Form 8-K, filed with the SEC on July 28, 2023 — read the filing on EDGAR.
Each item below shows how the 528 asset managers that disclosed a HORIZON THERAPEUTICS PUBLIC LIMITED CO. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Director Nominees: Gino Santini
HORIZON THERAPEUTICS PUBLIC LIMITED CO.’s own tally for this item (“Elect Director: Gino Santini”): 151,483,008 for, 5,400,292 against, per its Form 8-K filed July 28, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following directors were elected to serve for three-year terms expiring at the 2026 Annual General Meeting of Shareholders and until their respective successors are duly elected and qualified, or, if sooner, until the respective director's death, resignation, disqualification or removal.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AQR | 799,236,767 | 0 | 0 | 0 | For |
| Vanguard | 21,189,547 | 0 | 0 | 0 | For |
| New York Life | 9,246,987 | 0 | 0 | 0 | For |
| BlackRock | 5,214,897 | 0 | 0 | 0 | For |
| Fidelity | 3,085,979 | 23,368 | 0 | 0 | For |
| FRANKLIN MUTUAL SERIES FUNDS | 2,037,193 | 0 | 0 | 0 | For |
| MERGER FUND | 1,830,231 | 0 | 0 | 0 | For |
| TIAA | 1,159,808 | 0 | 0 | 0 | For |
| Charles Schwab | 926,423 | 0 | 0 | 0 | For |
| BNY Mellon | 802,961 | 13,385 | 0 | 0 | For |
| AMCAP FUND | 761,022 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 689,708 | 0 | 0 | 0 | For |
| Capital Group | 660,437 | 0 | 0 | 0 | For |
| State Street | 614,714 | 0 | 0 | 0 | For |
| Dimensional | 612,640 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 594,305 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 537,381 | 0 | 0 | 0 | For |
| Jackson National | 95,523 | 175,224 | 0 | 0 | Mixed |
| Legg Mason | 232,460 | 0 | 0 | 0 | For |
| Calamos | 228,495 | 0 | 0 | 0 | For |
| T. Rowe Price | 221,296 | 0 | 0 | 0 | For |
| First Trust | 216,404 | 0 | 0 | 0 | For |
| Franklin Templeton | 208,870 | 0 | 0 | 0 | For |
| Goldman Sachs | 183,831 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 160,299 | 0 | 0 | 0 | For |
Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.
Combines 5 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Director Nominees: James Shannon, M.D.
HORIZON THERAPEUTICS PUBLIC LIMITED CO.’s own tally for this item (“Elect Director: James Shannon, M.D.”): 131,479,967 for, 25,396,734 against, per its Form 8-K filed July 28, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following directors were elected to serve for three-year terms expiring at the 2026 Annual General Meeting of Shareholders and until their respective successors are duly elected and qualified, or, if sooner, until the respective director's death, resignation, disqualification or removal.”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AQR | 799,236,767 | 0 | 0 | 0 | For |
| Vanguard | 21,189,547 | 0 | 0 | 0 | For |
| New York Life | 9,243,772 | 3,215 | 0 | 0 | For |
| BlackRock | 5,214,897 | 0 | 0 | 0 | For |
| Fidelity | 3,085,979 | 23,368 | 0 | 0 | For |
| FRANKLIN MUTUAL SERIES FUNDS | 0 | 2,037,193 | 0 | 0 | Against |
| MERGER FUND | 1,830,231 | 0 | 0 | 0 | For |
| TIAA | 1,159,808 | 0 | 0 | 0 | For |
| Charles Schwab | 926,423 | 0 | 0 | 0 | For |
| BNY Mellon | 816,346 | 0 | 0 | 0 | For |
| AMCAP FUND | 761,022 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 689,708 | 0 | 0 | 0 | For |
| Capital Group | 660,437 | 0 | 0 | 0 | For |
| State Street | 0 | 614,714 | 0 | 0 | Against |
| Dimensional | 612,640 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 594,305 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 537,381 | 0 | 0 | 0 | For |
| Jackson National | 270,747 | 0 | 0 | 0 | For |
| Legg Mason | 232,460 | 0 | 0 | 0 | For |
| Calamos | 228,495 | 0 | 0 | 0 | For |
| T. Rowe Price | 221,296 | 0 | 0 | 0 | For |
| First Trust | 216,404 | 0 | 0 | 0 | For |
| Franklin Templeton | 6,443 | 202,427 | 0 | 0 | Against |
| Goldman Sachs | 0 | 183,831 | 0 | 0 | Against |
| Nushares ETF Trust | 160,299 | 0 | 0 | 0 | For |
Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.
Combines 5 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Director Nominees: Timothy P. Walbert
HORIZON THERAPEUTICS PUBLIC LIMITED CO.’s own tally for this item (“Elect Director: Timothy P. Walbert”): 142,310,378 for, 14,398,120 against, per its Form 8-K filed July 28, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following directors were elected to serve for three-year terms expiring at the 2026 Annual General Meeting of Shareholders and until their respective successors are duly elected and qualified, or, if sooner, until the respective director's death, resignation, disqualification or removal.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AQR | 799,236,767 | 0 | 0 | 0 | For |
| Vanguard | 21,189,547 | 0 | 0 | 0 | For |
| New York Life | 9,246,987 | 0 | 0 | 0 | For |
| BlackRock | 5,214,897 | 0 | 0 | 0 | For |
| Fidelity | 3,085,979 | 23,368 | 0 | 0 | For |
| FRANKLIN MUTUAL SERIES FUNDS | 2,037,193 | 0 | 0 | 0 | For |
| MERGER FUND | 1,830,231 | 0 | 0 | 0 | For |
| TIAA | 1,159,808 | 0 | 0 | 0 | For |
| Charles Schwab | 926,423 | 0 | 0 | 0 | For |
| BNY Mellon | 816,346 | 0 | 0 | 0 | For |
| AMCAP FUND | 761,022 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 689,708 | 0 | 0 | 0 | For |
| Capital Group | 660,437 | 0 | 0 | 0 | For |
| State Street | 614,714 | 0 | 0 | 0 | For |
| Dimensional | 612,640 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 594,305 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 537,381 | 0 | 0 | 0 | For |
| Jackson National | 270,747 | 0 | 0 | 0 | For |
| Legg Mason | 232,460 | 0 | 0 | 0 | For |
| Calamos | 228,495 | 0 | 0 | 0 | For |
| T. Rowe Price | 221,296 | 0 | 0 | 0 | For |
| First Trust | 216,404 | 0 | 0 | 0 | For |
| Franklin Templeton | 208,870 | 0 | 0 | 0 | For |
| Goldman Sachs | 183,831 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 160,299 | 0 | 0 | 0 | For |
Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.
Combines 17 wordings of this item as funds reported it.
58% Majority: yes · of votes cast
Description as filed by funds: Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in this Proxy Statement.
HORIZON THERAPEUTICS PUBLIC LIMITED CO.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of our named executive officers”): 91,107,568 for, 65,607,818 against, per its Form 8-K filed July 28, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 58% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AQR Arbitrage LLC | 0 | 2,286,000,000 | 0 | 0 | Against |
| BESSEMER TRUST CO | 0 | 2,045,000,000 | 0 | 0 | Against |
| Vontobel Asset Management S.A. | 0 | 1,678,000,000 | 0 | 0 | Against |
| Checchi Capital Advisers, LLC | 0 | 770,000,000 | 0 | 0 | Against |
| BROWN ADVISORY INC | 0 | 342,000,000 | 0 | 0 | Against |
| Meeder Advisory Services, Inc. | 0 | 202,000,000 | 0 | 0 | Against |
| Vanguard | 21,570,800 | 129,704 | 0 | 0 | For |
| BlackRock | 14,006,028 | 64,898 | 0 | 0 | For |
| Lazard | 0 | 12,000,000 | 0 | 0 | Against |
| New York Life | 0 | 9,246,987 | 0 | 0 | Against |
| Man Group plc | 0 | 8,612,890 | 0 | 0 | Against |
| Pentwater Capital Management LP | 0 | 7,592,720 | 0 | 0 | Against |
| FARALLON CAPITAL MANAGEMENT LLC | 6,771,784 | 0 | 0 | 0 | For |
| Fidelity | 114,501 | 6,111,269 | 0 | 0 | Against |
| Avoro Capital Advisors LLC | 6,130,279 | 0 | 0 | 0 | For |
| State Street | 4,923,656 | 3,300 | 0 | 0 | For |
| UBS | 0 | 3,621,538 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 3,209,518 | 0 | 0 | Against |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,944,597 | 0 | 0 | 0 | For |
| Renaissance | 0 | 2,658,785 | 0 | 0 | Against |
| Capital Group | 2,246,214 | 0 | 0 | 0 | For |
| DE Shaw | 0 | 2,235,861 | 0 | 0 | Against |
| Citadel | 2,126,605 | 0 | 0 | 0 | For |
| FRANKLIN MUTUAL ADVISERS LLC | 0 | 2,106,200 | 0 | 0 | Against |
| FRANKLIN MUTUAL SERIES FUNDS | 0 | 2,037,193 | 0 | 0 | Against |
Showing the 25 largest of 521 asset managers. See all 521 in the interactive database.
Combines 7 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023, and authorization of the Audit Committee to determine the auditors' remuneration.
HORIZON THERAPEUTICS PUBLIC LIMITED CO.’s own tally for this item (“2. Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 and the authorization of the Audit Committee of our Board of ”): 165,306,334 for, 3,134,859 against, per its Form 8-K filed July 28, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of HORIZON THERAPEUTICS PUBLIC LIMITED CO.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify PricewaterhouseCoopers LLP as Auditors and Authorise Their Remuneration” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| AQR | 799,236,767 | 0 | 0 | 0 | For |
| Vanguard | 21,189,547 | 0 | 0 | 0 | For |
| New York Life | 9,246,987 | 0 | 0 | 0 | For |
| BlackRock | 5,214,897 | 0 | 0 | 0 | For |
| Fidelity | 3,109,347 | 0 | 0 | 0 | For |
| FRANKLIN MUTUAL SERIES FUNDS | 2,037,193 | 0 | 0 | 0 | For |
| MERGER FUND | 1,830,231 | 0 | 0 | 0 | For |
| TIAA | 1,159,808 | 0 | 0 | 0 | For |
| Charles Schwab | 926,423 | 0 | 0 | 0 | For |
| BNY Mellon | 816,346 | 0 | 0 | 0 | For |
| AMCAP FUND | 761,022 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 689,708 | 0 | 0 | 0 | For |
| Capital Group | 660,437 | 0 | 0 | 0 | For |
| State Street | 614,714 | 0 | 0 | 0 | For |
| Dimensional | 612,640 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 594,305 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 537,381 | 0 | 0 | 0 | For |
| Jackson National | 270,747 | 0 | 0 | 0 | For |
| Legg Mason | 232,460 | 0 | 0 | 0 | For |
| Calamos | 228,495 | 0 | 0 | 0 | For |
| T. Rowe Price | 221,296 | 0 | 0 | 0 | For |
| First Trust | 216,404 | 0 | 0 | 0 | For |
| Franklin Templeton | 208,870 | 0 | 0 | 0 | For |
| Goldman Sachs | 183,831 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 160,299 | 0 | 0 | 0 | For |
Showing the 25 largest of 113 asset managers. See all 113 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | AQR | 799,236,767 |
| 2 | Vanguard | 21,189,547 |
| 3 | New York Life | 9,246,987 |
| 4 | BlackRock | 5,214,897 |
| 5 | Fidelity | 3,109,347 |
| 6 | FRANKLIN MUTUAL SERIES FUNDS | 2,037,193 |
| 7 | MERGER FUND | 1,830,231 |
| 8 | TIAA | 1,159,808 |
| 9 | Charles Schwab | 926,423 |
| 10 | BNY Mellon | 816,346 |
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | AQR Arbitrage LLC | 2,286,000,000 |
| 2 | BESSEMER TRUST CO | 2,045,000,000 |
| 3 | Vontobel Asset Management S.A. | 1,678,000,000 |
| 4 | Checchi Capital Advisers, LLC | 770,000,000 |
| 5 | BROWN ADVISORY INC | 342,000,000 |
| 6 | Meeder Advisory Services, Inc. | 202,000,000 |
| 7 | Lazard | 12,000,000 |
| 8 | BlackRock | 8,856,029 |
| 9 | Man Group plc | 8,612,890 |
| 10 | Pentwater Capital Management LP | 7,592,720 |
Shown as share counts, not percentages: no shares-outstanding figure has been matched to HORIZON THERAPEUTICS PUBLIC LIMITED CO. for the 2023-2024 season, so there is no denominator to divide by.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At HORIZON THERAPEUTICS PUBLIC LIMITED CO.'s shareholder meeting held July 27, 2023, in the 2023-2024 proxy season, 528 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 2,663 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of our named executive officers, as… — FOR was 58% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: HORIZON THERAPEUTICS PUBLIC LIMITED CO.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on July 28, 2023.
HORIZON THERAPEUTICS PUBLIC LIMITED CO. proxy season coverage: 2023-2024 (this page).
Download data (CSV): ballot items · votes by manager · column guide.